QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Drug–Drug Interactions and Pharmacovigilance

Test your understanding of the concepts covered by Drug–Drug Interactions and Pharmacovigilance: Recognising, Assessing and Characterising Safety Risks.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should a deliberate rechallenge generally not be treated as a routine pharmacovigilance test of an interaction?

Rechallenge can never provide useful evidence Rechallenge is generally a clinical decision and may expose the patient to avoidable risk Rechallenge is required before any interaction can be documented Rechallenge only applies to pharmacokinetic interactions

Question 2 of 10 Which potential regulatory measure may be appropriate when an interaction is sufficiently supported and clinically important?

Automatically withdraw both medicines from the market Consider contraindications, warnings, dosing recommendations, monitoring or other risk-minimisation measures Delete the interaction from individual case reports to avoid duplication Publish the interaction only in an internal database without considering product information

Question 3 of 10 Why is accurate representation of suspected interacting medicines in an ICSR important?

It ensures that the interaction is automatically confirmed It allows interaction-related cases to remain identifiable during case review and aggregate assessment It eliminates the need for a clinical narrative It determines the patient's treatment plan

Question 4 of 10 Why may a modest exposure increase be clinically important for one medicine but not another?

All medicines have the same exposure–response relationship Clinical relevance depends partly on therapeutic index, exposure–response characteristics and patient susceptibility Exposure changes matter only when they are caused by enzyme inhibition A modest increase is clinically relevant only if the event is serious

Question 5 of 10 Which exposure information would be most useful when evaluating whether a suspected interaction was clinically relevant?

Only the trade names of the two medicines Dose, dosing interval, duration, adherence, formulation, route and treatment changes Only the date on which the adverse event was reported The medicine's marketing authorisation date

Question 6 of 10 A suspected interaction involves enzyme induction. Which temporal consideration is particularly important?

Induction generally has no relationship to treatment duration Induction may require time to develop and may persist after the inducer is discontinued Induction always occurs immediately after the first dose Induction effects end as soon as the last dose is taken

Question 7 of 10 How should external pharmacokinetic or pharmacodynamic study results be used in pharmacovigilance assessment?

They should be applied automatically regardless of dose or clinical setting They provide evidence that should be interpreted in relation to routine exposure conditions and observed clinical outcomes They replace the need to review individual case details They establish the incidence of the interaction in all treated patients

Question 8 of 10 Which governance capability would best demonstrate control of interaction surveillance during an inspection?

A list of all theoretically possible interactions, without case or decision records Traceability from recognition and medical assessment through coding, follow-up, signal review and escalation decisions Evidence that every reported interaction was classified as confirmed A prescribing database maintained independently of pharmacovigilance processes

Question 9 of 10 Which statement best describes why an interaction can be clinically important without representing new intrinsic toxicity of either medicine?

Interactions alter only reporting behaviour, not patient risk Combined exposure can change concentration or pharmacological effect so that an adverse reaction occurs under conditions where each medicine alone may be tolerated Intrinsic toxicity is defined solely by the most recently initiated medicine An interaction is clinically important only when both medicines are individually toxic

Question 10 of 10 Why should the underlying disease and comorbidities be considered in a suspected interaction case?

They are irrelevant once a known interaction exists They may provide realistic alternative explanations or modify exposure and susceptibility They determine whether the case is reportable regardless of the event They replace the need to assess medicine exposure

Knowledge Assessment: Drug–Drug Interactions and Pharmacovigilance

Cookie Settings